A Phase 1-2 Study of AZD0754 CAR T-Cell Therapy in People With Advanced Prostate Cancer

Full Title

A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants with Metastatic Prostate Cancer: APOLLO

Purpose

Researchers want to find the best dose of AZD0754 for people with prostate cancer. The patients in this study have prostate cancer that has metastasized (spread).

AZD0754 is a form of treatment called CAR T-cell therapy, which is made of specialized white blood cells. If you take part in this study, we will collect some of your T cells. We will modify (change) them in a lab to make AZD0754.

You will have a very short course of chemotherapy to reduce the cells that can interfere with the effectiveness of the modified T cells. Then you will have one dose of AZD0754. This treatment is given intravenously (by vein).

Contact

For more information or to see if you can join this study, please call Dr. Susan Slovin’s office at 646-422-4470.